Drugs / SYS6043
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07424547 | Mar 2026 → Dec 2029 expected | breast cancer, metastatic neoplasm, ovarian cancer, prostate disorder +1 | Conjupro Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07241936 | Nov 2025 → Oct 2027 expected | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07415863 | Dec 2024 → Dec 2027 expected | — | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07708753 | Jul 2026 → Oct 2029 expected | fallopian tube cancer, primary peritoneal carcinoma, refractory malignant neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07415863 ↗ |
| Modality | Other / unclassified | “Different ADCs (DP303c/SYS6043/SYS6002/SYS6010)” NCT07241936 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07241936 ↗ |